Watch our webinar with Avecho Biotechnology, featuring CEO Dr Paul Gavin. A presentation followed by live Q&A with the audience.

Avecho Biotechnology Limited develops and commercialises innovative pharmaceutical products using its proprietary drug delivery system called TPM, which is proven to enhance the absorption of drugs in the body. Avecho’s lead asset is a proprietary cannabidiol (“CBD”) TPM soft-gel capsule currently undergoing Phase III clinical development for the treatment of insomnia. The product is targeting a unique registration opportunity with the Therapeutic Goods Administration (TGA) in Australia and is already the focus of a licensing deal with Sandoz, the largest generic pharmaceutical company in the world.
Management tells one side of the story. Sharewise clients get independent research and Advisor access across ASX, US and global markets.